Valuation: CSL Limited

Market Cap 57.77B 49.49B 46.31B 42.39B 79.55B 5,528B 80.6B 547B 213B 2,777B 217B 212B 9,185B P/E 2027 *
19.9x
P/E 2028 * 18x
Enterprise Value 66.9B 57.31B 53.62B 49.09B 92.12B 6,401B 93.34B 634B 247B 3,216B 251B 246B 10,636B EV / Sales 2027 *
4.25x
EV / Sales 2028 * 4.09x
Free-Float
99.97%
Yield 2027 *
2.5%
Yield 2028 * 2.64%
1 day-1.69%
1 week+23.30%
Current month+36.76%
1 month+38.66%
3 months+68.22%
6 months+9.81%
Current year-2.52%
1 week 134.6
Extreme 134.6
175.94
1 month 113.75
Extreme 113.75
175.94
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap.
2/23/26 Free

Director

263 0.0001%
2/23/26 Free 512 0.0001%
2/19/26 Fiscal year

Director

183 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-1.69%+23.30%-25.53%-36.93% 57.77B
+0.90%+3.80%+39.43%-1.22% 83.28B
+8.86%+129.20%+453.51%+30.65% 57.92B
-1.46%+0.19%-0.81%+29.66% 51.75B
+1.74%+4.43%+11.41%+172.02% 49.35B
+1.13%+3.31%+55.82%-18.22% 32.03B
+0.46%+6.37%+47.71%+96.99% 25.91B
+1.19%+9.17%+3.12%+228.73% 22.74B
-0.30%+4.45%+60.84%+124.17% 16.87B
-5.74%+1.91%+2.59%+825.47% 16.08B
Average -0.35%+18.61%+64.81%+145.13% 41.37B
Weighted average by Cap. -0.04%+24.07%+79.19%+77.50%

Financials

2027 *2028 *
Net sales 15.74B 13.48B 12.61B 11.55B 21.67B 1,506B 21.96B 149B 58.12B 756B 59.1B 57.81B 2,502B 16.28B 13.94B 13.04B 11.94B 22.41B 1,557B 22.71B 154B 60.1B 782B 61.11B 59.78B 2,587B
Net income 2.82B 2.41B 2.26B 2.07B 3.88B 270B 3.93B 26.68B 10.41B 135B 10.58B 10.35B 448B 3.16B 2.7B 2.53B 2.32B 4.35B 302B 4.4B 29.88B 11.65B 152B 11.85B 11.59B 502B
Net Debt 9.13B 7.82B 7.32B 6.7B 12.57B 873B 12.74B 86.44B 33.71B 439B 34.28B 33.53B 1,451B 8.73B 7.48B 7B 6.41B 12.02B 835B 12.18B 82.69B 32.25B 420B 32.79B 32.07B 1,388B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
26-08-21 A$168.30 -1.69% 2,686,531
26-08-20 A$171.20 +2.84% 3,463,800
26-08-19 A$166.48 +5.49% 3,879,713
26-08-18 A$157.82 +17.25% 3,707,429
26-08-17 A$134.60 -1.39% 865,737
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
120.64USD
Average target price
116.90USD
Spread / Average Target
-3.10%

Quarterly revenue - Rate of surprise